Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Alchemia Limited completes patient recruitment for HA-Irinotecan cancer drug trial  Join our daily free Newsletter

MENAFN - ProactiveInvestors - Australia - 04/02/2013

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - ProactiveInvestors - Australia) Alchemia (ASX: ACL) has recruited its 390th patient, giving it the full patient quota for the Phase III clinical trial of its lead cancer drug, HA-Irinotecan.

This final stage study compares the safety and efficacy of Alchemia's proprietary technology in combination with standard chemotherapy drug irinotecan against irinotecan alone in metastatic colorectal cancer patients.

The double blind trial is being conducted in second and third line patients.

Encouragingly, patients on the trial are continuing treatment for longer than anticipated before their disease progresses, which would have ended the trial.

Alchemia now expects to end the trial early in 2014 rather than in the second half of 2013 when an anticipated 350 patients experience disease progression.

The primary objective of the HyACT technology is to enhance existing drugs used for cancer chemotherapy to develop a new generation of anti-cancer drugs which demonstrates better efficacy than existing drugs.

 






  MENA News Headlines


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help